Thursday 16 October, 2025
Objectives: In prospective clinical trials pharmacokinetically guided dose adjustment was performed for paclitaxel and docetaxel [1, 2]. As target parameters…
Read morePoster: Oncology
Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions
Thursday 16 October, 2025
Objectives: Imatinib has been increasingly proposed for therapeutic drug monitoring (TDM), as trough concentrations (Cmin) correlate with response rates in…
Read moreSimulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients
Thursday 16 October, 2025
Objectives: Several population pharmacokinetic (PPK) and pharmacokinetic-pharmacodynamic (PK-PD) analyses have been performed with the anticancer drug imatinib. Inspired by the…
Read moreTumour Growth Inhibition In Preclinical Animal Studies: Steady-State Analysis Of Biomarker-Driven Models.
Thursday 16 October, 2025
Objectives: Three different models describing tumour growth inhibition (TGI) dynamics in xenografted mice are considered, two of which are biomarker-driven….
Read moreBiomarker-driven Models of Tumour Growth Inhibition in preclinical animal studies
Thursday 16 October, 2025
Objectives: A biomarker – in the context of mechanism-based PK-PD modelling – is a measurement that defines quantitatively a process…
Read moreClinical trial simulations of the anticancer agents- abiraterone and nilotinib
Thursday 16 October, 2025
Objectives: Food effects can have a significant impact on the bioavailability of oral anticancer drugs. The objective of this study was…
Read moreModel-based analysis of disease progression in pancreatic cancer based on registry data collected from the Surveillance, Epidemiology, and End Result (SEER) database
Thursday 16 October, 2025
Objectives: Pancreatic cancer is the fourth leading cause of cancer related deaths in United States. With most patients diagnosed with…
Read moreSemi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes.
Thursday 16 October, 2025
Objectives: To develop a semi mechanistic thrombocytopenia model of a new HDAC inhibitor in development, taking into account the pharmacological…
Read moreHematological toxicity modelling of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor, in patients suffering from solid tumors or lymphoma: influence of the disease-progression on the drug-induced thrombocytopenia.
Thursday 16 October, 2025
Objectives: To develop a semi-mechanistic PKPD model of thrombocytopenia, taking into account differences within patients, treated with abexinostat for either…
Read morePKPD-Modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size following axitinib treatment in metastatic renal cell carcinoma (mRCC) patients
Thursday 16 October, 2025
Objectives: Axitinib (Inlyta®) is a multi-targeted tyrosine kinase inhibitor with anti-angiogenic properties, approved for the treatment of metastatic renal cell…
Read more